Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.
Lisa M. Barroilhet, MD
Advertisement
Articles by Lisa M. Barroilhet, MD
PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Significantly Improves PFS Vs Chemoimmunotherapy in R/R Large B-Cell Lymphoma
2
AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis
3
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
4
Fixed-Duration Pirtobrutinib/Venetoclax/Rituximab Drives PFS Benefit in R/R CLL
5